tbuckley/cabot-search huggingface dataset:
Population-Based Primary Care Payment System in Hawaii
Authors: Stephen Kemble, Christopher Flanders, Michelle A. Mitchell
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New-Onset Diabetes, Longitudinal Trends in Metabolic Markers, and Risk of Pancreatic Cancer in a Heterogeneous Population
Authors: Brian Z. Huang, Stephen J. Pandol, Christie Y. Jeon, Suresh T. Chari, Catherine A. Sugar, Chun R. Chao, Zuo-Feng Zhang, Bechien U. Wu, Veronica Wendy Setiawan
Journal: Clinical Gastroenterology and Hepatology (2019)
Tolterodine Tedavisi ?-Bloker ile Tedavi Edilen Erkeklerde Aşırı Aktif Mesaneyi Düşündüren Depolama Semptomlarını İyileştirmektedir
Authors: Christopher Chapple a, Sender Herschorn, Paul Abrams, Franklin Sun, Marina Brodsky, Zhonghong Guan
Journal: European Urology (2009)
Two thirds of GP trainees have no plan to work full time after qualifying, survey finds
Authors: Abi Rimmer
Journal: BMJ (2019)

Less than a third of GP trainees plan to work full time in general practice the year after they qualify, a survey carried out by the King’s Fund has found.

The healthcare think tank surveyed 840 GP trainees in England.1 It found that just 27% intended to work full time (seven or more sessions a week) in general practice one year after qualifying, and only 5% thought they might do so 10 years after qualifying.

Just over two fifths (41%) said …
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Authors: David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes
Journal: Journal of the National Comprehensive Cancer Network (2019)

The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as "preferred interventions," whereas others are categorized as either "other recommended interventions" or "useful under certain circumstances."
Afterload mismatch in patients with hypertrophic nonobstructive cardiomyopathy.
Authors: Takahiko Miki, Yoshiyuki Yokota, Hisashi Fukuzaki
Journal: Circulation (1990)

To investigate the cardiac reserve of hypertrophic nonobstructive cardiomyopathy (HNCM), an echocardiographic study was performed before and during angiotensin II loading in 22 HNCM patients without left ventricular (LV) systolic dysfunction at rest and 8 normal subjects. LV end-diastolic dimension (LVDd) and time velocity integral (Ie) at aortic annulus were obtained as parameters of preload and forward ejection respectively. Responses of these indices to afterload stress were compared with clinical findings and right ventricular biopsy findings. Based on the reserve of forward ejection characteristics to afterload stress, 22 HNCM patients were divided into 2 groups; Group I: 9 cases with more than 15% decrease of Ie which corresponded to the value of mean - 1SD in normal subjects, Group II: 13 cases with a decrease of Ie less than 15%. There were no significant differences in echocardiographic findings between Group I and II before angiotensin II loading. On the other hand, Group I had a smaller increase of LVDd (p less than 0.05) to afterload stress, a higher incidence of ventricular tachycardia on a Holter electrocardiogram (p less than 0.05), lower maximal oxygen consumption with treadmil exercise test (p less than 0.01), and a larger value of LV end-diastolic pressure (p less than 0.05) than those in Group II, respectively. Although no difference in myocyte diameter was found between the 2 groups, myocardial fibrosis was more severe (p less than 0.001) and the incidence of moderate or severe disarray was higher (p less than 0.05) in Group I than in Group II. Thus, some HNCM patients cannot maintain forward ejection to afterload stress because of impaired preload reserve attributable to a greater stiffness of the left ventricle with severe myocardial lesion.
A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results
Authors: Todd A Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J Siegel, John F DiPersio, Amanda F Cashen, David D Hurd, Kristie A Blum, Nancy L Bartlett
Journal: Blood (2008)
The value of promoter methylation of the MGMT gene and IDH mutations in secondary glioblastomas.
Authors: Li Bie, Qian Yun Li
Journal: Journal of Clinical Oncology (2013)

e22193 Background: Several studies have observed a change in MGMT silencing and IDH1 mutation in secondary glioblastomas (sGBMs). However, reports about the prognostic value of promoter methylation of the MGMT gene and IDH mutations in secondary glioblastomas (sGBMs) are few in number. Methods: The study involved primary and secondary tumor tissue samples from 89 GBMs pts (P/S: 42/47) diagnosed and treated within the First Hospital of Jilin University from Jan 2006 to Nov 2011. After surgical treatment, all GBM pts were subjected to radiotherapy with concomitant administration of TMZ. Pts with GBM were screened for promoter status of MGMT gene, by the methylation-speciﬁc polymerase chain reaction (MSP), and, for IDH mutations by direct sequencing. Results: A total of 42 of 89 pts (47.2%) had primary GBMs (pGBMs) (Group 1), while 47 pts (52.8%) had secondary GBMs (Group 2). In Group 2, 23 pts (21/47, 44.7%) developed a sGBM through progression from a low grade glioma (LGG) WHO grade II and a secondary anaplastic gliomas (sAG) (Group 2a), whereas 26 pts (26/47, 55.3%) showed a direct malignant transformation from a LGG to a sGBM (Group 2b). MGMT methylation was observed in 38 (42.7%) GBMs, with a higher frequency in sGBMs than pGBMs (24/14, 51.1 vs. 33.3%; p = 0.008). MGMT methylation status was associated with increased median survival time in pGBMs and sGBMs pts. IDH1 mutations are present in the majority of sGBMs but rare in pGBMs (31/5, 66.0 vs. 11.9%; p &lt; 0.001). Group 2a had a higher frequency with IDH1 mutation than group 2b (18/12, 78.3 vs. 46.2%; p &lt; 0.01). The median survival time after malignant progression of all sGBMs pts with an IDH mutation was longer than in pts with wild-type IDH (3.2 vs. 1.1ys; p &lt; 0.01). IDH1 mutation had an improved outcome in group2a, which is compared with group 2b (3.9 ys vs. 2.1 ys; p &lt; 0.05). Conclusions: In our population, pts with sGBM and IDH mutation had a signiﬁcantly improved outcome. In addition, MGMT methylation is also a powerful prognostic marker in sGBM pts.
Purification of an MLL Partner Associated Complex (MPAC) Suggests a Common Role for MLL Fusion Partners in Transcriptional Elongation.
Authors: Robert K. Slany, Dorothee Mueller, Christian Bach, Deniz Zeisig, Maria-Paz Garcia-Cuellar, Sara Monroe, Arun Sreekumar, Ron Zhao, Alexey Nesvizhskii, Arul Chinnaiyan, Jay L. Hess
Journal: Blood (2006)
Reinforced Mini-BEAM Followed by Autologous Hematopoietic Stem Cell Infusion in Refractory Lymphoma: A Study of Feasibility and Efficacy
Authors: Chiara Rusconi, Anna Maria Nosari, Chiara Vanelli, Vittorio Ruggero Zilioli, Erika Ravelli, Claudia Maria Basilico, Livio Gargantini, Laura Marbello, Alfredo Molteni, Giovanni Grillo, Enrica Morra
Journal: Blood (2008)
Both Discordant and Concordant Bone Marrow (BM) Involvement Predict for a Poorer Outcome Independent of the IPI in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP.
Authors: Laurie H. Sehn, Mukesh Chhanabhai, Suman Singh, Wayne Saville, Dan Matso, John J. Spinelli, Joseph M. Connors, Randy D. Gascoyne
Journal: Blood (2007)
Effect of Vitreomacular Adhesion on Treatment Outcomes in the Ranibizumab for Edema of the Macula in Diabetes (READ-3) Study
Authors: Mohammad Ali Sadiq, Mohamed Kamel Soliman, Salman Sarwar, Aniruddha Agarwal, Mostafa Hanout, Sibel Demirel, Zubir S. Rentiya, Waqar Khan, Diana V. Do, Quan Dong Nguyen, Yasir J. Sepah
Journal: Ophthalmology (2015)
Multimodality Imaging in Infective Endocarditis
Authors: Paola A. Erba, Maria N. Pizzi, Albert Roque, Erwan Salaun, Patrizio Lancellotti, Pilar Tornos, Gilbert Habib
Journal: Circulation (2019)

Infective endocarditis (IE) is a complex disease with cardiac involvement and multiorgan complications. Its prognosis depends on prompt diagnosis that leads to an aggressive therapeutic management combining antibiotic therapy and early cardiac surgery when indicated. However, IE diagnosis always poses a challenge, and echocardiography remains diagnostically imperfect in cases of prosthetic valve IE or cardiac implantable electronic device infection. In recent years, other imaging modalities (computed tomography, magnetic resonance imaging, nuclear imaging) have experienced significant technical improvements, and their application to the detection of cardiac and extracardiac IE-related lesions seems to be a strategic way forward in the management of patients with suspected IE. However, the scientific evidence in the literature remains limited; current guidelines address the use of the multimodality imaging in the field of IE with caution; the incremental value of each technique and their combinations is debated; and their use varies across countries. Despite these limitations, healthcare providers and surgeons should be aware of the possibilities offered by the multimodal imaging approach when appropriate. Here, we emphasize the value of a multidisciplinary heart valve team, the endocarditis team, underlining the importance of cardiac and extracardiac imaging experts in playing a key role in informing the diagnosis and management of patients with IE. Illustrative cases, critical appraisal of contemporary data, and conceptual and practical suggestions for clinicians that may help to improve the prognosis of patients with IE are provided in this review article.
5-Androstene-3b,17b-Diol Administration of Mice Exposed to Total Body Irradiation Results in Rapid Reconstitution of Immature Bone Marrow Progenitor Cells and Synergizes with Thrombopoietin but Not with Granulocyte-Colony Stimulating Factor.
Authors: Fatima SF Aerts Kaya, Trudi P Visser, James M Frincke, Dwight R. Stickney, Chris L Reading, Gerard Wagemaker
Journal: Blood (2008)
A 3-Year Follow-Up of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) as Front Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL).
Authors: Jiong Hu, Yuan-Fang Liu, Yong-Mei Zhu, Zhan-Zhong Shi, Jun-Min Li, Li Wang, Yu Chen, Zhi-Xiang Shen
Journal: Blood (2005)
One size does not fit all: implementation of interventions for non-communicable diseases
Authors: João Breda, Kremlin Wickramasinghe, David H Peters, Ivo Rakovac, Brian Oldenburg, Bente Mikkelsen, Ruitai Shao, Cherian Varghese, Téa Collins, Kristen Wall, Jill Farrington, Nick Townsend
Journal: BMJ (2019)

Implementation of evidence based interventions for non-communicable diseases is slow in many countries, and <b>João Breda and colleagues</b> call for more support to help them adapt the recommendations to their local context
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer
Authors: Yanjing Li, Yiping He, William Butler, Lingfan Xu, Yan Chang, Kefeng Lei, Hong Zhang, Yinglu Zhou, Allen C. Gao, Qingfu Zhang, Daniel G. Taylor, Donghui Cheng, Suzette Farber-Katz, Rachid Karam, Tyler Landrith, Bing Li, Sitao Wu, Vickie Hsuan, Qing Yang, Hailiang Hu, Xufeng Chen, Melissa Flowers, Shannon J. McCall, John K. Lee, Bryan A. Smith, Jung Wook Park, Andrew S. Goldstein, Owen N. Witte, Qianben Wang, Matthew B. Rettig, Andrew J. Armstrong, Qing Cheng, Jiaoti Huang
Journal: Science Translational Medicine (2019)

Hormonal therapy targeting androgen receptor (AR) is initially effective to treat prostate cancer (PCa), but it eventually fails. It has been hypothesized that cellular heterogeneity of PCa, consisting of AR+ luminal tumor cells and AR- neuroendocrine (NE) tumor cells, may contribute to therapy failure. Here, we describe the successful purification of NE cells from primary fresh human prostate adenocarcinoma based on the cell surface receptor C-X-C motif chemokine receptor 2 (CXCR2). Functional studies revealed CXCR2 to be a driver of the NE phenotype, including loss of AR expression, lineage plasticity, and resistance to hormonal therapy. CXCR2-driven NE cells were critical for the tumor microenvironment by providing a survival niche for the AR+ luminal cells. We demonstrate that the combination of CXCR2 inhibition and AR targeting is an effective treatment strategy in mouse xenograft models. Such a strategy has the potential to overcome therapy resistance caused by tumor cell heterogeneity.
Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma (MM).
Authors: Chitra Hosing, Muzaffar H. Qazilbash, Partow Kebriaei, Sergio Giralt, Marilyn S. Davis, Beverly Rhodes, Veronica Smith, Elizabeth J. Shpall, John McMannis, Martin Korbling, Richard Champlin
Journal: Blood (2005)
Long-Term Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Reduces Arterial FDG Uptake
Authors: Charalambos Vlachopoulos, Iosif Koutagiar, Ioannis Skoumas, Dimitrios Terentes-Printzios, Evangelos Zacharis, Genovefa Kolovou, Kimon Stamatelopoulos, Loukianos Rallidis, Niki Katsiki, Helen Bilianou, Evangelos Liberopoulos, Antigoni Miliou, Pavlos Kafouris, Aleksandros Georgakopoulos, Vasiliki Gardikioti, Dimitrios Tousoulis, Constantinos D. Anagnostopoulos
Journal: JACC. Cardiovascular imaging (2019)

Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9i) reduce cardiovascular events ([1][1],[2][2]). 18F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography/computed tomography (PET/CT) successfully evaluates arterial inflammation and improves
Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS.
Authors: D. Haase, C. Steidl, J. Schanz, R. Schabla, M. Pfeilstöcker, T. Nösslinger, B. Hildebrandt, A. Kuendgen, M. Lübbert, B. Kunzmann, A. Giagounidis, C. Aul, L. Trümper, O. Krieger, C. Fonatsch, P. Valent, R. Stauder, U. Germing
Journal: Blood (2005)
Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation
Authors: Vinita Dhir, Lara Zibdawi, Harminder K Paul, Osvaldo Espin-Garcia, Christine I Chen, Michael Crump, Robert Kridel, Vishal Kukreti, John Kuruvilla, Donna E Reece, Rodger E Tiedemann, Suzanne Trudel, Anca Prica
Journal: Blood (2019)
Loss of Alveolar Attachments as a Pathomechanistic Link between Small Airway Disease and Emphysema
Authors: Rob Janssen, Emiel F. M. Wouters
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

of patients undergoing noninvasive respiratory support due to hypoxemic respiratory failure, to avoid any delay in endotracheal intubation.It is possible that prompt detection of treatment failure prevented muscle exhaustion-induced hypoventilation in failing patients.Finally, because in some patients (i.e., those with lower inspiratory effort) helmet NIV increased transpulmonary pressure swings, the authors suggest that helmet NIV is less able to limit lung stress than HFNC and that this treatment should be reserved for selected patients as a step-up support.Unfortunately, we fear that it is not possible to draw conclusions regarding this specific aspect from our results.However, global lung stress (estimated by transpulmonary pressure swings) is only one determinant of selfinflicted lung injury, and inspiratory effort seems the most important parameter to be taken into account in this setting.Helmet NIV allows the application of high positive end-expiratory pressure, which reduces inspiratory effort and prevents pendelluft-induced overstretch in the dependent lung, as well as other ventilatory heterogeneities, making spontaneous effort less injurious (7).Importantly, during lung injury, limiting transpulmonary pressure swings cannot prevent injurious inflation patterns or diaphragm injury if inspiratory effort is not reduced as well (5, 8).
Abstract 16057: Mortality and Resource Utilization in Pediatric Hypertrophic Cardiomyopathy Patients With and Without Genetic Disorders in the United States
Authors: Jonathan B Edelson, Heather Griffis, Danielle S Burstein, Xuemei Zhang, Joseph W Rossano, Kimberly Y Lin, Matthew J O’Connor
Journal: Circulation (2018)

Introduction: Hypertrophic cardiomyopathy (HCM) is the most common form of inherited cardiomyopathy in children, with variable etiologies, phenotypes, and associated genetic disorders (GD). However...
JAMA Network Articles of the Year 2019
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Functions of N6-methyladenosine and its role in cancer
Authors: Liuer He, Huiyu Li, Anqi Wu, Yulong Peng, Guang Shu, Gang Yin
Journal: Molecular Cancer (2019)

N6-methyladenosine (m6A) is methylation that occurs in the N6-position of adenosine, which is the most prevalent internal modification on eukaryotic mRNA. Accumulating evidence suggests that m6A modulates gene expression, thereby regulating cellular processes ranging from cell self-renewal, differentiation, invasion and apoptosis. M6A is installed by m6A methyltransferases, removed by m6A demethylases and recognized by reader proteins, which regulate of RNA metabolism including translation, splicing, export, degradation and microRNA processing. Alteration of m6A levels participates in cancer pathogenesis and development via regulating expression of tumor-related genes like BRD4, MYC, SOCS2 and EGFR. In this review, we elaborate on recent advances in research of m6A enzymes. We also highlight the underlying mechanism of m6A in cancer pathogenesis and progression. Finally, we review corresponding potential targets in cancer therapy.
The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas
Authors: Sabrina Croce, Tom Lesluyes, Carine Valle, Loubna M'Hamdi, Noémie Thébault, Gaëlle Pérot, Eberhard Stoeckle, Jean-Christophe Noël, Quitterie Fontanges, Mojgan Devouassoux-Shisheboran, Denis Querleu, Frédéric Guyon, Anne Floquet, Camille Chakiba, Laetitia Mayeur, Flora Rebier, Gaëtan Marie MacGrogan, Isabelle Soubeyran, Sophie Le Guellec, Frédéric Chibon
Journal: Clinical Cancer Research (2019)

Uterine leiomyosarcoma, which accounts for 7% of all soft-tissue sarcomas and 1%-3% of all uterine malignancies, is an aggressive tumor responsible for a significant proportion of uterine cancer-related deaths. While Federation Internationale des Gynaecologistes et Obstetristes (FIGO) stage is the most important prognostic factor, metastatic and relapse rates at stage I exceed 50% so it is currently impossible to predict the clinical outcome of stage I leiomyosarcomas. In 2010, our team published a transcriptomic signature composed of 67 genes related to chromosome biogenesis, mitosis control, and chromosome segregation. It has demonstrated its prognostic value in many cancer types and was recently successfully applied to formalin-fixed, paraffin-embedded sarcomas by NanoCind on NanoString technology, making another step forward toward its use in routine practice. Sixty uterine leiomyosarcomas at any stage, including 40 localized in the uterus (stage I), were analyzed with the NanoCind (CINSARC with NanoString) signature. Its prognostic value was evaluated for overall survival and relapse-free survival and compared in multivariate analysis with other prognostic markers like FIGO staging and genomic index. The NanoCind signature was able to split the heterogeneous group of uterine leiomyosarcomas of any stage including stage I into two distinct groups with different relapse-free survival and overall survival. These results were validated on an independent cohort of uterine leiomyosarcomas in The Cancer Genome Atlas consortium. The NanoCind signature is a powerful prognosticator that outperforms FIGO staging and the genomic index. The CINSARC signature is platform independent and "ready to use" and should now be used for randomization in future therapeutic trials.
Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids
Authors: Sarah E. LeBoeuf, Warren L. Wu, Triantafyllia R. Karakousi, Burcu Karadal, S. RaElle Jackson, Shawn M. Davidson, Kwok-Kin Wong, Sergei B. Koralov, Volkan I. Sayin, Thales Papagiannakopoulos
Journal: Cell Metabolism (2019)
Insufficient Evidence for Association of NOD2/CARD15 or Other Inflammatory Bowel Disease-Associated Markers with Gvhd or Other Outcomes in T-Replete, Unrelated Donor Transplantation Facilitated by the NMDP
Authors: Yume Nguyen, Abed Al-Lehibi, Elizabeth Gorbe, Ellen Li, Michael D Haagenson, Tao Wang, Stephen R Spellman, Stephanie J. Lee, Nicholas O Davidson
Journal: Blood (2008)
Nramp1 Promotes Efficient Macrophage Recycling of Iron Following Phenylhydrazine-Induced Hemolytic Anemia
Authors: Shan Soe-Lin, Bill Andriopoulos, Marc Andrews, Matthias Schranzhofer, Tanya Kahawita, Daniel Garcia Santos, Nabila Azad, Sameer Sadashiv Apte, Prem Ponka
Journal: Blood (2008)